Physician profile
Ashraf A Sabe
NPI 1093942815
$24,486.95
in general payments reported to CMS, 2019-2025
12 companies · $4,929 in 2025
The $4,929 reported for 2025 was more than what 82% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.15 · 2020: $2,414 · 2021: $2,580 · 2022: $2,518 · 2023: $7,186 · 2024: $4,790 · 2025: $4,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,454 · Consulting Fee: $6,100 · Food and Beverage: $4,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,453.95 |
| Consulting Fee | $6,100.00 |
| Food and Beverage | $4,352.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $9,866.13 | 2019-2025 | Mitris Resilia Mitral Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Atricure, INC. | $4,796.77 | 2021-2025 | Atriclip Laa Exclusion System, Isolator Surgical Ablation System, Synergy Ablation System |
| Procyrion, INC. | $4,200.00 | 2023-2024 | Aortix System |
| Medtronic, INC. | $2,964.00 | 2023-2025 | Simulus, Avalus, Corevalve Evolut R |
| Abbott Laboratories | $1,103.90 | 2021-2025 | Tendyne |
| Intuitive Surgical, INC. | $886.17 | 2023 | Da Vinci Surgical System |
| Bolton Medical INC | $288.50 | 2022-2024 | Relay Thoracic Stent-Graft With Plus Delivery System |
| Dilon Technologies, INC. | $166.35 | 2024 | Hemoblast Bellows |
| Baxter Healthcare | $136.45 | 2025 | Coseal |
| Astrazeneca Pharmaceuticals LP | $64.31 | 2022 | |
| Medtronic Vascular, INC. | $14.37 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Sabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.